Results 11 to 20 of about 77,174 (152)

Acute toxicity of temozolomide for the treatment of anaplastic astrocytoma: A case report

Glioma, 2021
Temozolomide is an orally administered chemotherapeutic drug that has become a standard treatment for malignant gliomas. Severe toxicity of temozolomide is rare, especially shortly after administration. We report a 37-year-old male patient diagnosed with
Yunni Diansari, Norman Djamaluddin, Ashita Hulwah   +2 more
doaj   +1 more source

XPA Enhances Temozolomide Resistance of Glioblastoma Cells by Promoting Nucleotide Excision Repair

Cell Transplantation, 2022
Glioblastoma is the most frequent, as well as aggressive kind of high-grade malignant glioma. Chemoresistance is posing a significant clinical barrier to the efficacy of temozolomide-based glioblastoma treatment.
Weimin Dai, An Wu, Yunping Li, Guofeng Yu, Xinjiang Yan   +4 more
doaj   +1 more source

A Strategy for Imidazotetrazine Prodrugs with Anti-cancer Activity Independent of MGMT and MMR [PDF]

, 2012
The imidazotetrazine ring is an acid-stable precursor and prodrug of highly-reactive alkyl diazonium ions. We have shown that this reactivity can be managed productively in an aqueous system for the generation of aziridinium ions with 96% efficiency. The
Hartley, J.A., Wheelhouse, Richard T., Li, Li, Garelnabi, EAE, Li, L, Elrashied A. E. Garelnabi, Kiakos, K, Wheelhouse, RT, Garelnabi, Elrashied A.E., Richard T. Wheelhouse, Roger M. Phillips, Hartley, JA, Phillips, Roger M., Nazira Karodia, Pletsas, D, Karodia, N, Dimitrios Pletsas, Kiakos, K., Karodia, Nazira, Phillips, Roger, Pletsas, Dimitrios, Li Li, Konstantinos Kiakos, John A. Hartley   +23 more
core   +1 more source

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation [PDF]

, 2011
Background: We analyzed prospectively whether MGMT (O(6)-methylguanine-DNA methyltransferase) mRNA expression gains prognostic/predictive impact independent of MGMT promoter methylation in malignant glioma patients undergoing radiotherapy with ...
Kreth Simone, Friedrich W. Kreth, Hans A Kretzschmar, Lutz Juergen, Ludwig C. Hinske, Friedrich W Kreth, Ledderose Carola, Kretzschmar, Hans A., Kreth, Friedrich-Wilhelm, Juergen Lutz, Eigenbrod, Sabina, Kreth, Simone, Tonn, Joerg C., Thon Niklas, Thon, Niklas, Eigenbrod Sabina, Joerg C Tonn, Hinske, Ludwig C., Egensperger Rupert, Kretzschmar Hans A., Carola Ledderose, Rupert Egensperger, Kreth Friedrich W., Joerg C. Tonn, Lutz, Juergen, Niklas Thon, Hans A. Kretzschmar, Kreth, Friedrich W., Egensperger, Rupert, Hinske Ludwig C., Hinske, Ludwig Christian, Ludwig C Hinske, Sabina Eigenbrod, Tonn Joerg C., Ledderose, Carola, Simone Kreth   +35 more
core   +1 more source

Restoration of Sensitivity in Chemo [PDF]

, 2013
Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Despite multimodal treatments including surgery, chemotherapy and radiotherapy the prognosis remains poor and relapse occurs regularly.
Schäfer, Andrea, Morfill, Gregor E., Schwenk-Zieger, Sabina, Shimizu, Tetsuji, Welz, Christian, Li, Yang-Fang, Boxhammer, Veronika, Zimmermann, Julia L., Klämpfl, Tobias G., Köritzer, Julia, Schlegel, Jürgen   +10 more
core   +1 more source

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Frontiers in Oncology, 2020
Glioblastoma, the most common primary central nervous system tumor, is characterized by extensive vascular neoformation and an area of necrosis generated by rapid proliferation.
Monserrat Llaguno-Munive, Monserrat Llaguno-Munive, Sebastián León-Zetina, Inés Vazquez-Lopez, María del Pilar Ramos-Godinez, Luis A. Medina, Luis A. Medina, Patricia Garcia-Lopez   +7 more
doaj   +1 more source

Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Oncology Reviews, 2011
Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor.
Wen-Jen Hwu, Ana E. Ayala, Ingrid M. Hernandez   +2 more
doaj   +1 more source

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

Frontiers in Pharmacology, 2022
Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht, V. Udaya Kumar, Ruchi Pandey, Ravichandiran Velayutham, Nitesh Kumar   +4 more
doaj   +1 more source

Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53 [PDF]

, 2013
YesThe antitumor prodrug temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-methylguanine-DNA-methyltransferase (E.C.
Phillips, Roger M., Wheelhouse, Richard T., Li, Li, Pletsas, D, Garelnabi, EAE, Li, L, Phillips, Roger, Garelnabi, Elrashied A.E., Wheelhouse, RT, Pletsas, Dimitrios   +9 more
core   +1 more source

Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Frontiers in Cell and Developmental Biology, 2022
Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation.
Mohummad Aminur Rahman, Mohummad Aminur Rahman, Agnete S. T. Engelsen, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesbøll, Even Birkeland, Dorota Goplen, Maria L. Lotsberg, Maria L. Lotsberg, Stian Knappskog, Stian Knappskog, Anne Simonsen, Anne Simonsen, Anne Simonsen, Martha Chekenya   +15 more
doaj   +1 more source